Ademi LLP is investigating Enfusion (NYSE: ENFN) for possible breaches of fiduciary duty and other violations of law in its transaction with Clearwater.

Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you.

In the transaction, Enfusion stockholders will receive only consideration equal to $11.25 per share consisting of $5.85 per share in cash and $5.40 per share in Clearwater Class A Common Stock, subject to certain pre-closing adjustments. Enfusion insiders will receive substantial benefits as part of change of control arrangements.

The transaction agreement unreasonably limits competing transactions for Enfusion by imposing a significant penalty if Enfusion accepts a competing bid. We are investigating the conduct of Enfusion’s board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.

We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250113529399/en/